Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations

We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diagnostic and interventional radiology (Ankara, Turkey) Jg. 26; H. 2; S. 131 - 139
Hauptverfasser:	Yang, Bo-Shuai, Liu, Ling-Xiao, Yuan, Min, Hou, Yi-Bin, Li, Qing-Tao, Zhou, Su, Shi, Yu-Xin, Gao, Bu-Lang
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Turkey Galenos Yayinevi Tic. Ltd 01.03.2020 Galenos Publishing House Turkish Society of Radiology
Schlagworte:	Ablation Ablation (Surgery) Cancer Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - therapy Catheter Ablation - methods Chemoembolization Chemoembolization, Therapeutic - methods Combined Modality Therapy - methods Comparative analysis Diagnostic Imaging - methods Disease-Free Survival Female Follow-Up Studies Humans Imaging Interventional Radiology Liver cancer Liver Neoplasms - diagnostic imaging Liver Neoplasms - surgery Liver Neoplasms - therapy Male Medical imaging equipment Medical prognosis Middle Aged Necrosis Radio frequency Retrospective Studies Survival Treatment Outcome Tumors
ISSN:	1305-3612, 1305-3825, 1305-3612
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations. A total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed. RFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3-48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS. RFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations.
AbstractList	PURPOSE We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations. METHODS A total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed. RESULTS RFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3–48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS. CONCLUSION RFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations. PURPOSEWe aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations.METHODSA total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed.RESULTSRFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3–48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS.CONCLUSIONRFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations. We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations. A total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed. RFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3-48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS. RFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations. We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations.PURPOSEWe aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations.A total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed.METHODSA total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed.RFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3-48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS.RESULTSRFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3-48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS.RFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations.CONCLUSIONRFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations. We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple imaging modalities for hepatocellular carcinomas (HCCs) in special (i.e., high-risk or unfavorable) locations compared with those in conventional locations. A total of 122 HCC patients were enrolled, including 85 patients (69.7%) with HCC in conventional locations and 37 (30.3%) with HCC in special locations. The clinical data, overall survival (OS), progression-free survival (PFS), and procedure-related adverse events were analyzed. RFA combined with TACE was successfully performed in all patients. Three complications (2.5%) occurred, with no significant difference between the conventional (n=1, 1.2%) and special (n=2, 5.4%) locations (P = 0.218). Complete tumor necrosis rate was not significantly different between the conventional (n=73, 85.9%) and special (n=34, 91.9%) locations at one-month imaging (P = 0.353). After a follow-up of 3-48 months, the PFS was 17 months for patients with HCC in conventional locations and 14 months for patients with HCC in special locations; one-year PFS rate was 68.1% in the conventional location group, not significantly (P = 0.741) different from 59.1% in the special location group. The OS was 28 months in the conventional location group while 32 months in the special location group. The cumulative one- and two-year OS rates were 89.9% and 63.3%, respectively, in the conventional location group, not significantly different from 96.3% and 65% in the special location group (P = 0.273). Age (P = 0.043) and tumor size (P < 0.001) were significant prognostic factors for OS, and tumor size (P < 0.001) was the only significant prognostic factor for PFS. RFA guided by multiple imaging modalities combined with TACE may be safe and effective for treating HCCs in special locations.
Audience	Academic
Author	Gao, Bu-Lang Yuan, Min Hou, Yi-Bin Yang, Bo-Shuai Liu, Ling-Xiao Shi, Yu-Xin Zhou, Su Li, Qing-Tao
Author_xml	– sequence: 1 givenname: Bo-Shuai surname: Yang fullname: Yang, Bo-Shuai – sequence: 2 givenname: Ling-Xiao surname: Liu fullname: Liu, Ling-Xiao – sequence: 3 givenname: Min surname: Yuan fullname: Yuan, Min – sequence: 4 givenname: Yi-Bin surname: Hou fullname: Hou, Yi-Bin – sequence: 5 givenname: Qing-Tao surname: Li fullname: Li, Qing-Tao – sequence: 6 givenname: Su surname: Zhou fullname: Zhou, Su – sequence: 7 givenname: Yu-Xin surname: Shi fullname: Shi, Yu-Xin – sequence: 8 givenname: Bu-Lang surname: Gao fullname: Gao, Bu-Lang
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32071022$$D View this record in MEDLINE/PubMed
BookMark	eNp1kkuP0zAUhSM0iHnAliWKxIZNix-J02yQRiMeIw1iA2vr-vqm9cixi5OAyi_h5-K080SgLBLZ53z2PTmnxVGIgYriJWfLmtfirXVpKRhvl3xVV-xJccIlqxdScXH04Pu4OB2Ga8bquuXVs-JYCtZwJsRJ8fvz5Ee39VS6HtYurMs-WvBu3C3Wk7NkywTWxS7R94kC7kowHkYXQ4mxNy5kwU83bsoxQRggjZQc-BI31EfqTfTu10HdxVRuaAtjRPJ-8pBKhIQuxB5KF8phSzg7fcS9YXhePO3AD_Ti5n1WfPvw_uvFp8XVl4-XF-dXC6xrPi5g1aK0smFYoUE0hsgaBgTCMCkVk6ajxradBVCMdwKUgLZSVUO2VYKYPCsuD1wb4VpvU44h7XQEp_cLMa11HsuhJ91ajisjjUXTVfmQlSLVYcXQIpOc88x6d2BtJ9OTRQo5Fv8I-ngnuI1exx-6YTUXar7MmxtAijnvYdS9G-bAIFCcBi1kvVKMqbbJ0td_Sa_jlEKOSou6alaqEZW8V60hD-BCF_O5OEP1uRKyaTNxVi3_ocqPpd5hLlzn8vojw6uHg95NeNurLKgOAkxxGBJ1Gt24_7GZ7LzmTM_11bm-eq6v3tf3_iJ3tlvyfwx_ACRC9ts
CitedBy_id	crossref_primary_10_3389_fonc_2025_1530951 crossref_primary_10_1016_j_engmed_2024_100037 crossref_primary_10_3389_fonc_2020_573316 crossref_primary_10_4251_wjgo_v13_i12_1896 crossref_primary_10_1016_j_ejrad_2024_111619
ContentType	Journal Article
Copyright	COPYRIGHT 2020 Galenos Yayinevi Tic. Ltd. 2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.dirjournal.org/en/about-dir-1010 Copyright 2020 by the Turkish Society of Radiology 2020
Copyright_xml	– notice: COPYRIGHT 2020 Galenos Yayinevi Tic. Ltd. – notice: 2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.dirjournal.org/en/about-dir-1010 – notice: Copyright 2020 by the Turkish Society of Radiology 2020
CorporateAuthor	Shanghai Public Health Clinical Center, Fudan University, Shanghai, China Shanghai Institute of Medical Imaging, Shanghai, China Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
CorporateAuthor_xml	– name: Shanghai Institute of Medical Imaging, Shanghai, China – name: Shanghai Public Health Clinical Center, Fudan University, Shanghai, China – name: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FE 8FG 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BENPR BGLVJ CCPQU DWQXO EDSIH FYUFA GHDGH HCIFZ K9. KB0 M0S M1P NAPCQ P5Z P62 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.5152/dir.2019.18540
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Technology Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials ProQuest Central Technology Collection ProQuest One ProQuest Central Turkey Database Health Research Premium Collection Health Research Premium Collection (Alumni) SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Turkey Database ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals - Free url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1305-3612
EndPage	139
ExternalDocumentID	oai_doaj_org_article_9d1c8b3bdcbf4b0a86e6fc40cdc03111 PMC7051260 A623792353 32071022 10_5152_dir_2019_18540
Genre	Journal Article
GroupedDBID	--- 29G 2WC 53G 5GY 6PF 7RV 7X7 88E 8FE 8FG 8FI 8FJ AAWTL AAYXX ABUWG ADBBV AENEX AFFHD AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS ARAPS BAWUL BENPR BGLVJ BKEYQ BMSDO BPHCQ BVXVI CCPQU CITATION DIK EBS EDSIH EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH ITC M1P NAPCQ OK1 OVT P62 PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNS RPM TR2 UKHRP 3V. C1A CGR CUY CVF ECM EIF NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c551t-a89c3d370c4cbccbbeedb0aea2b033603bfe7d9fdaa601f2a62a94647ed962e03
IEDL.DBID	7RV
ISICitedReferencesCount	5
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000518142400009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1305-3612 1305-3825
IngestDate	Mon Nov 03 22:02:47 EST 2025 Tue Nov 04 01:47:03 EST 2025 Fri Sep 05 06:45:53 EDT 2025 Sat Nov 29 14:50:24 EST 2025 Tue Nov 11 11:06:29 EST 2025 Tue Nov 04 18:27:05 EST 2025 Thu Jan 02 22:57:36 EST 2025 Tue Nov 18 20:57:02 EST 2025 Sat Nov 29 01:51:37 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c551t-a89c3d370c4cbccbbeedb0aea2b033603bfe7d9fdaa601f2a62a94647ed962e03
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work.
ORCID	0000-0001-8334-2759 0000-0001-8202-0053 0000-0003-3223-5798 0000-0003-2972-1445 0000-0002-8008-3445 0000-0002-4597-1711 0000-0002-8015-2017 0000-0003-4668-0737
OpenAccessLink	https://www.proquest.com/docview/2547867243?pq-origsite=%requestingapplication%
PMID	32071022
PQID	2547867243
PQPubID	2032277
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_9d1c8b3bdcbf4b0a86e6fc40cdc03111 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7051260 proquest_miscellaneous_2358600697 proquest_journals_2547867243 gale_infotracmisc_A623792353 gale_infotracacademiconefile_A623792353 pubmed_primary_32071022 crossref_citationtrail_10_5152_dir_2019_18540 crossref_primary_10_5152_dir_2019_18540
PublicationCentury	2000
PublicationDate	2020-03-01
PublicationDateYYYYMMDD	2020-03-01
PublicationDate_xml	– month: 03 year: 2020 text: 2020-03-01 day: 01
PublicationDecade	2020
PublicationPlace	Turkey
PublicationPlace_xml	– name: Turkey – name: Ankara
PublicationTitle	Diagnostic and interventional radiology (Ankara, Turkey)
PublicationTitleAlternate	Diagn Interv Radiol
PublicationYear	2020
Publisher	Galenos Yayinevi Tic. Ltd Galenos Publishing House Turkish Society of Radiology
Publisher_xml	– name: Galenos Yayinevi Tic. Ltd – name: Galenos Publishing House – name: Turkish Society of Radiology
SSID	ssj0055914
Score	2.2197063
Snippet	We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by multiple... PURPOSE We aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by... PURPOSEWe aimed to evaluate the safety and effectiveness of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) guided by...
SourceID	doaj pubmedcentral proquest gale pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	131
SubjectTerms	Ablation Ablation (Surgery) Cancer Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - therapy Catheter Ablation - methods Chemoembolization Chemoembolization, Therapeutic - methods Combined Modality Therapy - methods Comparative analysis Diagnostic Imaging - methods Disease-Free Survival Female Follow-Up Studies Humans Imaging Interventional Radiology Liver cancer Liver Neoplasms - diagnostic imaging Liver Neoplasms - surgery Liver Neoplasms - therapy Male Medical imaging equipment Medical prognosis Middle Aged Necrosis Radio frequency Retrospective Studies Survival Treatment Outcome Tumors
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQhRAXxDeBgoyExCk0tbN2fCyIigOtOIDUm2WPHRqpm1S7WST-SX9uZ-zsaiOEuHCNJ4qdefbM2OM3jL3zEa2qibIkYpSy9hJKbyooHdSK-MWVD0nTX_X5eXNxYb7tlfqinLBMD5x_3JEJx9B46QP4tvaVa1RULdQVBEA85lu96PVsg6m8BqObfJzL2dI5LwZBma4Rbbc4QlNBGV3mA3aOtjz2zFFi7f9zbd4zTvPEyT1LdPqQPZhcSH6Su_6I3Yn9Y3bvbDokf8JuzqYkQd4tUw0ivhxCcrfLn5suxMBXLnRDu8pZ1L-58zkhjiP6MFBGAdqd5WMqJU4pn4hRjspdDnHph6vp5iZHd5dfojUbB9r9p3RWDlSZqB-Wjnc9X-fS9pzMZUL3U_bj9PP3T1_KqQBDCehIjaVrDMggdQU1eADv0aCiCqITvpJSVdK3UQfTBucwrmuFU8KZWtU6BqNErOQzdtAPfXzBuFDNIjStRvfG1cYL3zinfZQLnKSt9qpg5VYPFiZ2ciqScWUxSiG9WdSbJb3ZpLeCvd_JX2dejr9KfiS17qSITzs9QJTZCWX2XyjDzxEoLM167Ba46fICDo74s-wJepHExLiQBTucSeJshXnzFlZ2Wi3WVhCpmtKixua3u2Z6kzLg-jhsUEYuGkW80rpgzzMKd0OSIjmKomB6hs_ZmOctfXeZuMQ1LsoY0r78Hz_pFbsvaDciZegdsoNxtYmv2V34NXbr1Zs0QW8BCQFFvA priority: 102 providerName: Directory of Open Access Journals
Title	Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations
URI	https://www.ncbi.nlm.nih.gov/pubmed/32071022 https://www.proquest.com/docview/2547867243 https://www.proquest.com/docview/2358600697 https://pubmed.ncbi.nlm.nih.gov/PMC7051260 https://doaj.org/article/9d1c8b3bdcbf4b0a86e6fc40cdc03111
Volume	26
WOSCitedRecordID	wos000518142400009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1305-3612 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0055914 issn: 1305-3612 databaseCode: P5Z dateStart: 20050301 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1305-3612 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0055914 issn: 1305-3612 databaseCode: 7X7 dateStart: 20050301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1305-3612 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0055914 issn: 1305-3612 databaseCode: 7RV dateStart: 20050301 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1305-3612 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0055914 issn: 1305-3612 databaseCode: BENPR dateStart: 20050301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1305-3612 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0055914 issn: 1305-3612 databaseCode: PIMPY dateStart: 20050301 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Turkey Database customDbUrl: eissn: 1305-3612 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0055914 issn: 1305-3612 databaseCode: EDSIH dateStart: 20050301 isFulltext: true titleUrlDefault: https://search.proquest.com/turkey providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagRYgL70egrIyExCk0a2ft5IRa1AokdrWqAC1cLL_SRuomZR9I_BN-LjOOd9kIwYWLD_FYsTXjmfF4_A0hL40Hq1p6niIwSpobblNTZjbVNheILy6MC5z-ICeTYjYrpzHgtoxplRudGBS1ay3GyA8ZAk8JyXL-5upbilWj8HY1ltC4TvaHaLtBnuXZ540mBmd52BW1xdteOAp1oI1gwdkhGAzM6ypfwxQx8LFjlAJ2_58aesdE9dMnd-zR6Z3_Xcldcjt6ovSoE5175Jpv7pOb43jX_oD8HMdcQ1rPQykjOm9d8NrT83XtvKML7eq2WnTJ2D-oNl1eHYVpwHkbCDDIS1ehIjlmjoKoU5CReevnpr2MD0ApeM30AoziqsVLBMyKpRYLHDXtXNO6ofgWFEei1Q2b5CH5dHry8e27NNZxSC34Y6tUF6XljsvM5tZYawzYZZNpr5nJOBcZN5WXrqyc1nA8rJgWTJe5yKV3pWA-44_IXtM2_gmhTBQjV1QSvCSdl4aZQmtpPB_BXq-kEQlJN4xUNoKcY62NSwWHHWS8AsYrZLwKjE_Iqy39VQfv8VfKY5SLLRXCcocP7eJcxV2uSje0heHGWVPlsMRCeFHZPLPOgvIcDuF3KFUKlQdMy-r4BgIWhzBc6gicUQR0HPGEHPQoYdPbfvdGtlRUOkv1W7AS8mLbjSMxka7x7Rpo-KgQCE8tE_K4E-PtkjgL_iZLiOwJeG_N_Z6mvgiQ5BJ0O5yMn_57Ws_ILYbhipDCd0D2Vou1f05u2O-rerkYhL2L7UyGthiQ_eOTyfRsEAIl0E5HX-Hb9P14-uUXHTlZow
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKQcCFHRooYCQQp9CMnbGTA0JlqVp1ZsShSHMz3tJG6iTtLKD-E34Fv5H3nMwwEYJbD1xjZ7HzVvvz9wh5aTx41dzzGIlR4tRwG5s8sbG2qUB-cWFc-NMDORpl43H-eYP8XJ6FQVjl0iYGQ-1qi2vkOwyJp4RkKX93dh5j1SjcXV2W0GjE4tBffIeUbfb24CP831eM7X06-rAft1UFYgvRwTzWWW654zKxqTXWGgNewiTaa2YSzkXCTeGlywunNSQrBdOC6TwVqfQuF8wnHJ57hVwFOy4RQibHqwQPgvNeU0QXd5ch9WpIIiFiYDvgoBBHlr-BKcGFljUnGGoF_OkR1lxiF6655v_2bv9vM3eH3GojbbrbqMZdsuGre-T6sMUS3Cc_hi2WkpaTUKqJTmoXspL4eFE67-hUu7Iupg3Y_IJq0-AGKQzbwCMcxUVsOg8V1xEZC6pMQQcmtZ-Y-rQ94EohK6An4PTnNW6SIOqXWizgVNUTTcuK4llXvBOjimAEHpAvlzIvD8lmVVd-i1Amsr7LCglRoE5zw0ymtTSe98GWFdKIiMRLwVG2JXHHWiKnCpI5FDQFgqZQ0FQQtIi8XvU_a-hL_trzPcrhqhfSjocL9fRYtVZM5a5nM8ONs6ZIYYiZ8KKwaWKdBefQ68HrUIoVGkf4LKvbMx4wOKQZU7sQbCNhZZ9HZLvTE4ya7TYvZVm1RnWmfgtyRF6smvFOBApWvl5AH97PBNJvy4g8atRmNSTOQjzNIiI7CtUZc7elKk8C5boE3wWZ_-N_f9ZzcmP_aDhQg4PR4RNyk-HSTIArbpPN-XThn5Jr9tu8nE2fBbtBydfLVrdfKrKzMw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiple+imaging+modality-guided+radiofrequency+ablation+combined+with+transarterial+chemoembolization+for+hepatocellular+carcinoma+in+special+locations&rft.jtitle=Diagnostic+and+interventional+radiology+%28Ankara%2C+Turkey%29&rft.au=Yang%2C+Bo-Shuai&rft.au=Liu%2C+Ling-Xiao&rft.au=Yuan%2C+Min&rft.au=Hou%2C+Yi-Bin&rft.date=2020-03-01&rft.issn=1305-3612&rft.eissn=1305-3612&rft.volume=26&rft.issue=2&rft.spage=131&rft.epage=139&rft_id=info:doi/10.5152%2Fdir.2019.18540&rft.externalDBID=n%2Fa&rft.externalDocID=10_5152_dir_2019_18540
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1305-3612&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1305-3612&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1305-3612&client=summon